Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.

Q3 Psychology

Central nervous system agents in medicinal chemistry Pub Date : 2019-01-01 DOI:10.2174/1871524919666181126124846

Neeraj Mishra, Sawarni Sharma, Rahul Deshmukh, Anoop Kumar, Ruchika Sharma

{"title":"Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.","authors":"Neeraj Mishra, Sawarni Sharma, Rahul Deshmukh, Anoop Kumar, Ruchika Sharma","doi":"10.2174/1871524919666181126124846","DOIUrl":null,"url":null,"abstract":"Introduction: Parkinson's Disease (PD) is one of the most common age-related neurodegenerative disorders which is marked with the loss of dopaminergic neurons. The present study performed on the nose to brain delivery of selegiline hydrochloride loaded nano lipid carrier, suggests that the nasal route is a good mean of targeting the drug directly into the brain.Methods and materials: Nanostructured lipid carriers were prepared by using hot homogenization. Selegiline hydrochloride loaded NLCs and rotenone treatment were given at a dose of 10 mg/kg administered from 14th day to 28th day. Behavioral parameters were determined at 7th, 14th, 21st and 28th day. On the 28th day, animals were sacrificed for biochemical estimation.Results: The optimized drug loaded NLC formulation has shown 93±5.25% entrapment efficiency and 51.96% loading capacity. Optimized NLCs formulation has shown 70% release within 10 hours and after that, the release of the drug is sustained up to 22 hours (97%). Pharmacological action of the drug was found to restore the behavioral parameters in rotenone-induced rats.Conclusion: Nano Lipid Carrier (NLCs) therapeutics has emerged as a prominent method for the treatment of Parkinson's Disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy of neurotherapeutics. It is concluded from the studies that, Selegiline HCl loaded nano lipid carrier which was administered through nasal route has the potential to be used in the management therapy of Parkinson's disease.","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":"19 1","pages":"46-56"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871524919666181126124846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Psychology","Score":null,"Total":0}

引用次数: 22

Abstract

Introduction: Parkinson's Disease (PD) is one of the most common age-related neurodegenerative disorders which is marked with the loss of dopaminergic neurons. The present study performed on the nose to brain delivery of selegiline hydrochloride loaded nano lipid carrier, suggests that the nasal route is a good mean of targeting the drug directly into the brain.

Methods and materials: Nanostructured lipid carriers were prepared by using hot homogenization. Selegiline hydrochloride loaded NLCs and rotenone treatment were given at a dose of 10 mg/kg administered from 14th day to 28th day. Behavioral parameters were determined at 7th, 14th, 21st and 28th day. On the 28th day, animals were sacrificed for biochemical estimation.

Results: The optimized drug loaded NLC formulation has shown 93±5.25% entrapment efficiency and 51.96% loading capacity. Optimized NLCs formulation has shown 70% release within 10 hours and after that, the release of the drug is sustained up to 22 hours (97%). Pharmacological action of the drug was found to restore the behavioral parameters in rotenone-induced rats.

Conclusion: Nano Lipid Carrier (NLCs) therapeutics has emerged as a prominent method for the treatment of Parkinson's Disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy of neurotherapeutics. It is concluded from the studies that, Selegiline HCl loaded nano lipid carrier which was administered through nasal route has the potential to be used in the management therapy of Parkinson's disease.

查看原文本刊更多论文

盐酸塞来吉兰纳米脂载体鼻给药治疗帕金森病的研究进展及特点。

帕金森氏病(PD)是最常见的与年龄相关的神经退行性疾病之一，其特征是多巴胺能神经元的丧失。本研究通过鼻腔给药给药，将盐酸塞勒吉兰负载纳米脂质载体，提示鼻腔给药是一种很好的靶向药物直接进入大脑的方法。方法与材料:采用热均质法制备纳米脂质载体。以10 mg/kg的剂量给药NLCs和鱼藤酮，第14天至第28天。分别于第7、14、21、28天测定行为参数。第28天处死动物进行生化评价。结果:优化后的包封率为93±5.25%，载药量为51.96%。优化后的NLCs制剂在10小时内释放率为70%，10小时后药物持续释放达22小时(97%)。药理作用发现该药物可恢复鱼藤酮诱导大鼠的行为参数。结论:纳米脂质载体(NLCs)疗法已成为治疗帕金森病(PD)的重要方法，因为它提供了靶向递送并提高了神经疗法的治疗效果。本研究认为，经鼻给药的盐酸塞来吉兰纳米脂质载体具有应用于帕金森病管理治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Central nervous system agents in medicinal chemistry Psychology-Neuropsychology and Physiological Psychology

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： Central Nervous System Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new central nervous system agents. Containing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Central Nervous System Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.